584 related articles for article (PubMed ID: 27732800)
1. Pharmacology of Antisense Drugs.
Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
3. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
Bennett CF; Swayze EE
Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
[TBL] [Abstract][Full Text] [Related]
4. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
[TBL] [Abstract][Full Text] [Related]
5. Use of antisense oligonucleotides in functional genomics and target validation.
Ravichandran LV; Dean NM; Marcusson EG
Oligonucleotides; 2004; 14(1):49-64. PubMed ID: 15104896
[TBL] [Abstract][Full Text] [Related]
6. Progress in antisense technology.
Crooke ST
Annu Rev Med; 2004; 55():61-95. PubMed ID: 14746510
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide therapeutics: 25 years agrowing.
Goodchild J
Curr Opin Mol Ther; 2004 Apr; 6(2):120-8. PubMed ID: 15195922
[TBL] [Abstract][Full Text] [Related]
9. Antisense and RNA interference approaches to target validation in pain research.
Kurreck J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
[TBL] [Abstract][Full Text] [Related]
10. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of antisense oligonucleotide inhibitors of protein expression.
Cooper SR; Taylor JK; Miraglia LJ; Dean NM
Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217
[TBL] [Abstract][Full Text] [Related]
12. Modulating the expression of disease genes with RNA-based therapy.
Wood M; Yin H; McClorey G
PLoS Genet; 2007 Jun; 3(6):e109. PubMed ID: 17604456
[TBL] [Abstract][Full Text] [Related]
13. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
15. Antisense approaches to immune modulation for transplant and autoimmune diseases.
Mourich DV; Marshall NB
Curr Opin Pharmacol; 2005 Oct; 5(5):508-12. PubMed ID: 16087396
[TBL] [Abstract][Full Text] [Related]
16. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
Mahato RI; Cheng K; Guntaka RV
Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
[TBL] [Abstract][Full Text] [Related]
17. Antisense technology: A review.
Crooke ST; Liang XH; Baker BF; Crooke RM
J Biol Chem; 2021; 296():100416. PubMed ID: 33600796
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of action of antisense drugs.
Crooke ST
Biochim Biophys Acta; 1999 Dec; 1489(1):31-44. PubMed ID: 10806995
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
20. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
